BAVARIAN NORDIC A/S (BV3.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BV3 - DK0015998017 - Common Stock
26.89 EUR
+0.21 (+0.79%)
Taking everything into account, BV3 scores 6 out of 10 in our fundamental rating. BV3 was compared to 83 industry peers in the Biotechnology industry. BV3 has an excellent financial health rating, but there are some minor concerns on its profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on BV3. These ratings would make BV3 suitable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year BV3 was profitable.
- In the past year BV3 had a positive cash flow from operations.
- In multiple years BV3 reported negative net income over the last 5 years.
- Of the past 5 years BV3 4 years had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 16.13%, BV3 belongs to the top of the industry, outperforming 89.16% of the companies in the same industry.
- With an excellent Return On Equity value of 18.58%, BV3 belongs to the best of the industry, outperforming 86.75% of the companies in the same industry.
- BV3 has a better Return On Invested Capital (13.14%) than 86.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.13% | ||
| ROE | 18.58% | ||
| ROIC | 13.14% |
ROA(3y)4.78%
ROA(5y)2.73%
ROE(3y)6.02%
ROE(5y)3.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 35.50%, BV3 belongs to the best of the industry, outperforming 91.57% of the companies in the same industry.
- BV3's Operating Margin of 36.21% is amongst the best of the industry. BV3 outperforms 91.57% of its industry peers.
- BV3 has a Gross Margin (54.33%) which is comparable to the rest of the industry.
- BV3's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.21% | ||
| PM (TTM) | 35.5% | ||
| GM | 54.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.91%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BV3 is still creating some value.
- Compared to 1 year ago, BV3 has more shares outstanding
- Compared to 5 years ago, BV3 has more shares outstanding
- The debt/assets ratio for BV3 has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 7.31 indicates that BV3 is not in any danger for bankruptcy at the moment.
- BV3 has a Altman-Z score of 7.31. This is amongst the best in the industry. BV3 outperforms 81.93% of its industry peers.
- The Debt to FCF ratio of BV3 is 0.10, which is an excellent value as it means it would take BV3, only 0.10 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 0.10, BV3 belongs to the best of the industry, outperforming 95.18% of the companies in the same industry.
- A Debt/Equity ratio of 0.01 indicates that BV3 is not too dependend on debt financing.
- BV3 has a better Debt to Equity ratio (0.01) than 81.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.1 | ||
| Altman-Z | 7.31 |
ROIC/WACC1.73
WACC7.59%
2.3 Liquidity
- BV3 has a Current Ratio of 3.84. This indicates that BV3 is financially healthy and has no problem in meeting its short term obligations.
- BV3 has a Current ratio of 3.84. This is in the better half of the industry: BV3 outperforms 73.49% of its industry peers.
- A Quick Ratio of 2.43 indicates that BV3 has no problem at all paying its short term obligations.
- With a Quick ratio value of 2.43, BV3 perfoms like the industry average, outperforming 56.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.84 | ||
| Quick Ratio | 2.43 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 39.44% over the past year.
- Looking at the last year, BV3 shows a quite strong growth in Revenue. The Revenue has grown by 13.47% in the last year.
- The Revenue has been growing by 53.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)39.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%414.42%
Revenue 1Y (TTM)13.47%
Revenue growth 3Y44.42%
Revenue growth 5Y53.88%
Sales Q2Q%32.58%
3.2 Future
- BV3 is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.41% yearly.
- Based on estimates for the next years, BV3 will show a small growth in Revenue. The Revenue will grow by 3.09% on average per year.
EPS Next Y54.87%
EPS Next 2Y-4.62%
EPS Next 3Y1.7%
EPS Next 5Y4.41%
Revenue Next Year9.45%
Revenue Next 2Y-0.91%
Revenue Next 3Y-0.48%
Revenue Next 5Y3.09%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 11.85, the valuation of BV3 can be described as very reasonable.
- Compared to the rest of the industry, the Price/Earnings ratio of BV3 indicates a rather cheap valuation: BV3 is cheaper than 93.98% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.47. BV3 is valued rather cheaply when compared to this.
- Based on the Price/Forward Earnings ratio of 21.09, the valuation of BV3 can be described as rather expensive.
- BV3's Price/Forward Earnings ratio is rather cheap when compared to the industry. BV3 is cheaper than 83.13% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of BV3 to the average of the S&P500 Index (24.26), we can say BV3 is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.85 | ||
| Fwd PE | 21.09 |
4.2 Price Multiples
- BV3's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BV3 is cheaper than 93.98% of the companies in the same industry.
- BV3's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BV3 is cheaper than 95.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.4 | ||
| EV/EBITDA | 3.81 |
4.3 Compensation for Growth
- BV3's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BV3 has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y-4.62%
EPS Next 3Y1.7%
5. Dividend
5.1 Amount
- BV3 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:BV3 (1/14/2026, 7:00:00 PM)
26.89
+0.21 (+0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-12 2026-03-12/amc
Inst Owners28.69%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap2.13B
Revenue(TTM)6.89B
Net Income(TTM)2.44B
Analysts84.44
Price Target34.14 (26.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.05%
PT rev (3m)-29.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-32.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.93%
Revenue NY rev (3m)-2.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.85 | ||
| Fwd PE | 21.09 | ||
| P/S | 2.31 | ||
| P/FCF | 12.4 | ||
| P/OCF | 5.08 | ||
| P/B | 1.21 | ||
| P/tB | 2.23 | ||
| EV/EBITDA | 3.81 |
EPS(TTM)2.27
EY8.44%
EPS(NY)1.28
Fwd EY4.74%
FCF(TTM)2.17
FCFY8.06%
OCF(TTM)5.29
OCFY19.68%
SpS11.63
BVpS22.23
TBVpS12.06
PEG (NY)0.22
PEG (5Y)N/A
Graham Number33.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.13% | ||
| ROE | 18.58% | ||
| ROCE | 18.66% | ||
| ROIC | 13.14% | ||
| ROICexc | 16.9% | ||
| ROICexgc | 40.21% | ||
| OM | 36.21% | ||
| PM (TTM) | 35.5% | ||
| GM | 54.33% | ||
| FCFM | 18.64% |
ROA(3y)4.78%
ROA(5y)2.73%
ROE(3y)6.02%
ROE(5y)3.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.91%
GM growth 5Y1.2%
F-Score8
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.1 | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 262.4% | ||
| Cap/Sales | 26.84% | ||
| Interest Coverage | 81.71 | ||
| Cash Conversion | 97.94% | ||
| Profit Quality | 52.5% | ||
| Current Ratio | 3.84 | ||
| Quick Ratio | 2.43 | ||
| Altman-Z | 7.31 |
F-Score8
WACC7.59%
ROIC/WACC1.73
Cap/Depr(3y)229.46%
Cap/Depr(5y)231.44%
Cap/Sales(3y)29.07%
Cap/Sales(5y)36.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%414.42%
EPS Next Y54.87%
EPS Next 2Y-4.62%
EPS Next 3Y1.7%
EPS Next 5Y4.41%
Revenue 1Y (TTM)13.47%
Revenue growth 3Y44.42%
Revenue growth 5Y53.88%
Sales Q2Q%32.58%
Revenue Next Year9.45%
Revenue Next 2Y-0.91%
Revenue Next 3Y-0.48%
Revenue Next 5Y3.09%
EBIT growth 1Y125.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.77%
EBIT Next 3Y18.67%
EBIT Next 5Y19.09%
FCF growth 1Y262.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y316.96%
OCF growth 3YN/A
OCF growth 5YN/A
BAVARIAN NORDIC A/S / BV3.DE FAQ
Can you provide the ChartMill fundamental rating for BAVARIAN NORDIC A/S?
ChartMill assigns a fundamental rating of 6 / 10 to BV3.DE.
What is the valuation status of BAVARIAN NORDIC A/S (BV3.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to BAVARIAN NORDIC A/S (BV3.DE). This can be considered as Undervalued.
How profitable is BAVARIAN NORDIC A/S (BV3.DE) stock?
BAVARIAN NORDIC A/S (BV3.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of BAVARIAN NORDIC A/S (BV3.DE) stock?
The Price/Earnings (PE) ratio for BAVARIAN NORDIC A/S (BV3.DE) is 11.85 and the Price/Book (PB) ratio is 1.21.
What is the financial health of BAVARIAN NORDIC A/S (BV3.DE) stock?
The financial health rating of BAVARIAN NORDIC A/S (BV3.DE) is 8 / 10.